Clene 10-Q: $3.9M Q3 'Net Income' Is Non-Cash; Cash Covers Only to Mid-Q1 2027
CLNN sits 25% above its 52-week low of $3.015.
Summary
Clene's Q3 profit is entirely non-cash warrant and derivative remeasurement; the operating loss widened to $6.3 million and $9.9 million of cash funds operations only into mid-Q1 2027, with a going-concern warning and a $2.0 million minimum-cash covenant still in force.
Key Events · Earnings and Guidance · CLNN
-
Q3 Profit Is Non-Cash Remeasurement
Net income of $3.9 million was driven by $10.3 million of total other income, including a $7.5 million change in fair value of common stock warrant liabilities and a $3.4 million change in fair value of derivative liabilities — non-cash mark-to-market entries, not cash generated.
-
Operating Loss Widened
Loss from operations was $6.3 million versus $5.6 million a year earlier, on total revenue of just $56,000; nine-month net loss was $17.6 million with $11.7 million of operating cash burn.
-
Going Concern and Cash Covenant
Management states substantial doubt about continuing as a going concern beyond one year from issuance, and the 2024 SSCP Notes require at least $2.0 million of unrestricted cash to avoid acceleration of the full balance.
-
Balance Sheet in Deficit
Cash and cash equivalents were $9.9 million at September 30, 2026 against total liabilities of $36.965 million, leaving a stockholders' deficit of $14.808 million.
Analysis · CLNN · Life Sciences
The headline profit is an accounting artifact, not a business turnaround. Clene's $3.9 million of Q3 net income rests on $10.3 million of other income, of which $7.5 million is a change in fair value of common stock warrant liabilities and $3.4 million a change in fair value of derivative liabilities — non-cash mark-to-market gains driven by the share price and valuation inputs, not cash coming in. Strip those out and the operating loss actually widened to $6.3 million from $5.6 million a year ago on $56,000 of revenue. The balance sheet is the real story: $9.9 million of cash against $36.965 million of total liabilities leaves a $14.808 million stockholders' deficit, and management repeats that substantial doubt exists about continuing as a going concern beyond one year. The 2024 SSCP Notes also require at least $2.0 million of unrestricted cash at all times or the full balance can be accelerated. With $15.4 million of near-term debt principal and interest due and a $1.6 million manufacturing capex commitment, another raise is close to certain — and the NDA submitted to the FDA in October 2026, with a response expected before the end of 2026, is the swing factor for both approval and the warrant proceeds tied to it.
How filings like this one have moved
In the 30 days to Nov 17, 2026, 48.3% of the 2133 measured filings Wiseek scored 8 moved their stock by 5% or more by the next session's close. The median move was -0.28%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, CLNN was trading at $3.77 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $53.6M. The 52-week trading range was $3.02 to $13.50. This filing was assessed with negative market sentiment and an importance score of 8 out of 10.